Company intelligence / Profile preview
Vera Therapeutics
Brisbane, California, United Statesveratx.com ↗
- Ownership
- Public · VERA
- Employees
- ~125
- Development stage
- Phase 3
01
Overview
Vera’s lead candidate atacicept demonstrated sustained eGFR stabilization through a Phase 2b trial in IgAN. The pivotal Phase 3 ORIGIN trial was initiated in June 2023. MAU868 completed a Phase 2 trial showing clinically meaningful reductions in BK viral activity with good tolerability. VT‑109 was recently licensed from Stanford University as a next-generation BAFF/APRIL dual-inhibitor for B cell mediated diseases.[2][6][7]
- Therapeutic areas
- ImmunologyInfectious DiseasesNephrology
- Modalities
- Fusion proteins (e.g., TACI-Fc fusion protein)[2][5]Monoclonal antibodies[2][5]
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Exclusive license agreement with Stanford University for VT‑109 technology[7]Collaborations with CROs and CMOs for clinical trials and manufacturing support[6]
04
Financials
- Market cap
- $2.2B
- Total revenue
- $0
- Enterprise value
- $1.9B
Beyond the preview
Go deeper on Vera Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vera Therapeutics.